Ivera Medical Corporation Announces Patent Award for Curos® Port Protectors
Published: Jun 13, 2012
SAN DIEGO, June 13, 2012 /PRNewswire/ -- Ivera Medical Corporation announced today that the United States Patent & Trademark Office (USPTO) will issue a new continuation patent for its innovative Curos® disinfecting port protector technology on June 26, 2012. U.S. Patent No. 8,206,514 will cover key aspects of disinfecting caps designed to be used with luer-activated IV valves to disinfect and clean the IV port.
IV therapy is the primary route for drug therapy in the acute care setting. However, traditional IV access management techniques, including "scrub the hub" protocols have failed to protect patients as evidenced by the approximately 87 percent of bloodstream infections associated with the presence of some type of intravascular device.
Ivera Medical's Curos Port Protector is a simple, innovative, disposable medical device that effectively disinfects luer-activated needleless valves, killing the organisms associated with patient bloodstream infection. With two dispenser optionsthe Curos Strip or individual Curosnurses can conveniently comply with disinfection protocols by simply peeling the foil seal off the distinctive green cap and twisting Curos over the top of any luer-activated IV access port or needleless valve. Inside Curos a 70% IPA (isopropyl alcohol) saturated sponge-like foam automatically provides effective, consistent and reliable passive disinfection of the port. The use of Curos eliminates training and technique-related issues while providing an unequivocal indicator that an IV access site is clean.
"This patent further strengthens our patent protection within the disinfection cap arena," stated Bob Rogers, chief executive officer of Ivera Medical. "We continue to develop our intellectual property to ensure that Ivera is well-positioned to bring new and better disinfection solutions to market."
About Ivera Medical
Ivera Medical Corporation is focused on the design, development, manufacture, marketing and sale of products that help healthcare providers reduce facility-acquired patient infections. Curos®, manufactured in Carlsbad, CA, is the first disinfecting cap to be marketed in the U.S. and has received FDA's 510(k) market clearance. For more information about Curos and Ivera Medical, visit the website at http://www.iveramed.com.
Chief Executive Officer
Ivera Medical Corp.
SOURCE Ivera Medical Corporation